Earl Binns filed the lawsuit Earl Binns v. Bristol-Myers Squibb Company et al, Case No. 3:17-cv-03028, US District Court, District of New Jersey on May 2, 2017, claiming that he developed coronary heart disease and congestive heart failure as a result of taking Saxagliptin.
Saxagliptin is used to help lower blood sugar levels in persons with type 2 diabetes mellitus. The FDA approved Onglyza (Saxagliptin) in 2009.
In his lawsuit, Binn claims that Bristol-Myers Squibb and Astrazeneca allegedly knew that there was a "significant, increased risk" of adverse events associated with Saxagliptin.
"Despite such knowledge, defendants knowingly, purposely and deliberately failed to adequately warn plaintiff, patients, consumers, medical providers and the public of the increased risk of serious injury associated with using Saxagliptin including but not limited to heart failure, congestive heart failure, cardiac failure, and death related to those events," according to the complaint.
Binn's lawsuit also alleges that the drug manufacturers failed to perform adequate testing concerning the safety of Saxagliptin or provide sufficient training to sales representatives who sold the products.
Other Saxagliptin lawsuits have also been filed, alleging that the makers of Onglyza and Kombiglyze XR failed to warn people who allegedly suffered congestive heart failure or other heart disease after taking the medications.
READ MORE ONGLYZA AND KOMBIGLYZE XR LEGAL NEWS
In April 2016, the FDA issued a drug safety communication, adding heart failure risk warnings to labels of type 2 diabetes medicines that contain saxagliptin and Alogliptin.
"Type 2 diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease," the FDA wrote in its warning. "Heart failure can result in the heart not being able to pump enough blood to meet the body’s needs."
Astrazeneca added heart failure risk warnings to Onglyza and Kombiglyze XR package labels in 2016.